Pharmacological interventions for clozapine-induced hypersalivation

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Syed, Rebecca ^a   Au, Katie ^b   Cahill, Caroline ^c   Duggan, Lorna ^c   He, Yanling ^d   Udu, Victor ^c   Xia, Jun ^e  

^a King's College Hospital ^*  (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST ANDREW S HOSPITAL   (United Kingdom)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e Bridge House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ASCORBIC ACID; ASTEMIZOLE; CLOZAPINE; DIPHENHYDRAMINE; DOXEPIN; GAMMA ORYZANOL; HERBACEOUS AGENT; MODAFINIL; PLACEBO; PROPANTHELINE BROMIDE;

BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; ECG ABNORMALITY; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; HERBAL MEDICINE; HUMAN; HYPERSALIVATION; LIVER FUNCTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA;

EID: 55049138638     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005579.pub2     Document Type: Review

References (55)

1. Fan 1996 {published data only} Fan QZ, Zhang LY, Duan H, Yu SW, Bu CG, Zhao HQ. Effectiveness of HuangYuanSan in the treatment of clozapine-induced hypersalivation: A control study. Sichuan Mental Health 1996;9(3):169-170.
2. Gong 1998 {published data only} Gong GQ, Yuan LX, Tan D, Li HJ, Zhao LX, Hu CF, Yang XT, Li XW, Lu CJ, Chen HM, Liu G, Yi WZ, Zhou SC, Zheng LB. Effectiveness of diphenhydramine, propantheline, hismanal and placebo in the treatment of clozapine-induced hypersalivation: A double blind control study. Clinical Journal of Psychiatry 1998;31(3):138.
3. Kang 1993 {published data only} Kang B, Liu YC, Zhang YP, Han Y, Fan LZ, Zhou J. Effect of suo quan pill for reducing clozapine induced salivation. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1993;13(6): 347-8, 325.
4. Kreinin 2005 {published data only} Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross over study. International Clinical Psychopharmacology 2006;21(2):99-103.
5. Li 1993 {published data only} Li ZX, Song ZM, Cheng PF, Li CL, Xiang XY, Shi H. Hismanal treatment of clozapine-induced hypersalivation: A double blind study. Journal of Clinical Psychiatry 1993;3(1):34- 35.
6. Li 2004 {published data only} Li Y. Effectiveness of oryzanol in the treatment of clozapine-induced salivation reaction. Journal of Nursing Science 2004;19(21):72-73. [: 116649]
7. Lin 1999 {published data only} Lin H. A double blind control study of propantheline and placebo in the treatment of clozapine-induced hypersalivation. Chinese Journal of Nervous Mental Disorders 1999;25(5):316-317.
8. Lu 1998 {published data only} Lu XB, Xue SJ, Yang BZ. Diphenhydramine treatment of clozapine-induced hypersalivation. SiChuan Mental Health 1998;11(1):35-37.
9. Qian 1996 {published data only} Qian QK, Gao ZX. Application of WuDanSan in accupunture points for treatment of clozapine-induced hypersalivation. Shanghai Archives of Psychiatry 1996;8(2):103.
10. Ren 2001 {published data only} Ren QT, Zhao CL, Ma XQ. The therapeutic efficacies of oryzanolum and doxepin on saloviation caused by clozapine. Practical Clinical Medicine 2001;2(2):31-32.
11. Wang 1998 {published data only} Wang SB, Song W, Gu WM. Doxepin and hismanal treament of clozapine-induced hypersalivation. Shanghai Archives of Psychiatry 1998;10(3):176-177.
12. Yang 1997 {published data only} Yang MZ, Zue SJ, Wen QQ. Effectiveness of diphenhydramine and propantheline in treatment of clozapine-induced hypersalivation: A double blind control study. GuangDong Medicine 1997;18(11):731.
13. Yao 1994 {published data only} Yao HX, Qu HF, Li GH. Effectiveness of propantheline and hismanal in treatment of clozapine-induced hypersalivation: a double blind control study. Journal of Clinical Psychiatry 1994;4(1):4.
14. Yuan 2000 {published data only} Yuan CM, Zhao XY, Han QY. A control study of the effectiveness of SuoQuanWan and doxepin in the treatment of clozapine-induced hypersalivation. Chinese Journal of Psychiatry 2000;33(4):206.
15. Zhou 1996 {published data only} Zhou HH, Zhang Q. A double blinded control study of the effectiveness of doxepin and propatheline in the treatment of clozapine-induced hypersalivation. Journal of Clinical Psychiatry 1996;6:300.
16. Xu 1997 {published data only} Xu HD, Dong AZ, Zhang TT, Shu WJ. Diphenhydramine for clozapine-induced salivation at various dosage levels. New Drugs and Clinical Remedies 1997;16(4):205-206.
17. Ya-Mei 2001 {published data only} Ya-Mei B, Chao-Cheng L, Jen-Yeu C, Win-Chien L. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: A randomised, double-blind, placebo-controlled, cross-over study [Therapeutic Effect of Pirenzepine for Clozapine-Induced Hypersalivation: A Randomised, Double-Blind, Placebo-Controlled, Cross Over Study]. Journal of Clinical Psychopharmacology 2001;21(6):608-611.
18. Zhai 1992 {published data only} Zhai. Hismal treatment for clozapine induced hypersalivation. Chinese Journal of Nervous and Mental Diseases 1992.
19. Kumar 2008 {unpublished data only} Modafinil for clozapine related adverse effects in people with schizophrenia or schizoaffective disorders in remission: a randomized, placebo controlled trial. Ongoing study Ongoing.
20. Li 2008 {unpublished data only} A randomised, double blind, placebo controlled trial of tabellae belladonnae compositae for clozapine induced hypersalivation. Ongoing study Unstated, currently in planning stage.
21. Altman 1996 Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200. [: OLZ020600]
22. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA Aug 1996;276(8):637-9.
23. Ben-Aryeh 1996 Ben-Aryeh H, Jungerman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biological Psychiatry 1996;39 (11):946-9.
24. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997; 315:600.
25. Brodkin 1996 Brodkin E, Pelton G, Price L. Treatment of clozapine-induced parotid gland swelling. American Journal of Psychiatry 1996;152:445.
26. Corrigan 1995 Corrigan F, MacDonald S, Reynolds G. Clozapine-induced hypersalivation and the alpha2 adrenoceptor. British Journal of Psychiatry 1995;167:412.
27. Curtin 2002a Curtin F, Altman D, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine 2002;21(15):2131-44.
28. Curtin 2002b Curtin F, Elbourne D, Altman D. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine 2002;21(15):2145-59.
29. Curtin 2002c Curtin F, Elbourne D, Altman D. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Statistics in Medicine 2002;21(15):2161-73.
30. Davydov 2000 Davydov L, Botts S. Clozapine-induced hypersalivation. Annals of Pharmacotherapy 2000;34:662-5.
31. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
32. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
33. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
34. Elbourne 2002 Elbourne D, Altman D, Higgins J, Curtin F, Worthington H, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
35. Fleiss 1984 Fleiss JL. The crossover study. The design and analysis of clinical experiments. Chichester: John Wiley & Sons, 1984.
36. Goodnick 2002 Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother May 2002;3(5):479-98.
37. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83 876-83.
38. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
39. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2005.
40. Hinkes 1996 Hinkes R, et al.Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea.. Journal of Clinical Psycho-pharmacology 1996; 16:462-3.
41. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
42. Rabinowitz 1996 Rabinowitz T, Frankenburg F, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biological Psychiatry 1996; 40(11):1132-4.
43. Reinstein 1999 Reinstein, M, Sirotovskya, L, Chasonov, M. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Journal of clinical drug investigation 1999;17:97-102.
44. Robinson 1995 Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. American Journal of Psychiatry 1995;152:297-8.
45. Rogers 2000 Rogers D, Shramko J. Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy 2000;20(9):1092-5.
46. Schmauss 1989 Schmauss M, Wolff R, Erfurth A, Ruther E. Tolerability of long term clozapine treatment. Psychopharmacology (Berl) 1989;99 supplement:S105-8.
47. Spivak 1997 Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine-induced hypersalivation.. International Journal of Clinical Psychopharmacology 1997;12:213- 215.
48. Taylor 2007 Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. Ninth. Informa Healthcare, 2007.
49. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
50. Wahlbeck 1999 Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine versus 'typical' neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 4.
51. Wang 2007 Wang G, Mao B, Xiong ZY, Fan T, Chen XD, Wang L, Lin GJ, Guo J, Chang J, Wu TX, Li TX. The quality of reporting of randomised trials of traditional chinesemedicine: a survey of 13 randomly selected journals from mainland China. Clin Ther July 2007;29(7):1456-67.
52. Young 1998 Young C, Bowers M, Mazure C. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998;24(3):381-90.
53. Yung 1993 Yung CX. Effectiveness of applying WuDanSan to accupunture point in treatment of clozapine-induced hypersalivation.. Journal of NanTung Medical School 1993;13:23.
54. Zheng 1994 Zheng YP, Lin KM, Zhao JP, Zhang MY, Yong D. Comparative study of diagnostic systems: Chinese Classificationof Mental Disorders-Second Edition versus DSM-III-R. Comprehensive Psychiatry 1994;35(6):441-9. [MEDLINE: 7867317]
55. Zorn 1994 Zorn S, Jones S, Ward K, Liston D. Clozapine is a potent and selective muscarinic M4 receptor agonist. European Journal of Pharmacology 1994;269:R1-2.